Novo Nordisk (NOVOB DC) has received a warning letter related to post-marketing adverse drug experience inspection conducted at the Plainsboro facility in 2025
Importance
Level 1
#NOVO NORDISK A/S#NOVOB.DC#EU SESSION#US SESSION#EUROPEAN EQUITIES
© 2026 Newsquawk. All rights reserved.